KEYVIBE-006
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
- NCT05298423 ↗
- Completed
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on KEYVIBE-006 (pembrolizumab/vibostolimab in unresectable stage III non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYVIBE-006 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- pembrolizumab/vibostolimab; durvalumab; cisplatin; pemetrexed; etoposide; carboplatin; paclitaxel; thoracic radiotherapy
- Arms
- pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy · Experimental
- chemotherapy+radiotherapy+durvalumab · Active comparator
- Enrollment
- 610
- Primary outcomes
- Number of Participants Who Experience at Least One Adverse Event (AE)
- Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- May 3, 2022
- Primary completion
- Jun 15, 2026
- Results posted
- No
- Registry record
- NCT05298423 · updated Aug 28, 2026